AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PACB · NASDAQ · Medical - Devices

PacBio (PACB)

Builds HiFi sequencing platforms centered on Revio, Vega, and consumables.

$1.46

vs last close+0.10 (+7.35%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	56	58	39	36	40	39	37	40	38	45	37	39
Cost of revenue	38	49	28	30	30	29	39	25	23	28	24	26
Gross profit	18	10	11	6	10	10	−1	15	15	17	13	13
	100	97	93	182	74	163	428	60	54	58	51	57
Research & development	48	45	43	38	26	27	29	23	23	23	20	23
Selling, general & administrative	43	46	42	36	44	41	40	36	31	34	31	33
Other expenses	9	7	7	108	5	94	358	1	0	1	0	1
Operating income	−82	−88	−81	−176	−64	−153	−429	−45	−39	−41	−38	−45
	5	5	3	3	3	156	3	3	1	1	30	0
Interest expense	4	4	4	4	4	3	2	2	2	2	−2	2
Other non-operating income	−9	−8	−7	−6	−7	−158	−4	−5	−3	−3	−28	−2
Income before tax	−78	−83	−78	−173	−61	3	−426	−42	−38	−40	−8	−45
Income tax expense	−11	−1	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−67	−82	−78	−173	−61	2	−426	−42	−38	−40	−8	−45
Net income	−67	−82	−78	−173	−61	2	−426	−42	−38	−40	−8	−45
EPS, basic	−$0.26	−$0.31	−$0.29	−$0.64	−$0.22	$0.01	−$1.44	−$0.14	−$0.13	−$0.13	−$0.03	−$0.14
EPS, diluted	−$0.26	−$0.31	−$0.29	−$0.64	−$0.22	$0.01	−$1.44	−$0.14	−$0.13	−$0.13	−$0.03	−$0.14
Weighted average shares, basic	255	265	270	272	273	283	297	300	301	302	306	311
Weighted average shares, diluted	255	267	270	272	273	307	297	300	301	302	306	311
EBITDA	−69	−61	−63	−155	−41	16	−52	−36	−31	−34	−6	−38
Depreciation & amortization	5	18	12	14	16	11	373	5	4	5	4	5
EBIT	−74	−79	−75	−170	−57	5	−425	−40	−36	−38	−10	−43